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Original research article
The economic burden of stroke care in
England, Wales and Northern Ireland:
Using a national stroke register to
estimate and report patient-level
health economic outcomes in stroke
Xiang-Ming Xu1, Emma Vestesson1, Lizz Paley1,
Anita Desikan2, David Wonderling3, Alex Hoffman1,
Charles DAWolfe2, Anthony G Rudd2 and Benjamin D Bray4;
on behalf of the SSNAP collaboration
Abstract
Introduction: Stroke registries are used in many settings to measure stroke treatment and outcomes, but rarely include
data on health economic outcomes. We aimed to extend the Sentinel Stroke National Audit Programme registry of
England, Wales and Northern Ireland to derive and report patient-level estimates of the cost of stroke care.
Methods: An individual patient simulation model was built to estimate health and social care costs at one and five years
after stroke, and the cost-benefits of thrombolysis and early supported discharge. Costs were stratified according to age,
sex, stroke type (ischaemic or primary intracerebral haemorrhage) and stroke severity. The results were illustrated using
data on all patients with stroke included in Sentinel Stroke National Audit Programme from April 2015 to March 2016
(n¼ 84,184).
Results: The total cost of health and social care for patients with acute stroke each year in England, Wales and Northern
Ireland was £3.60 billion in the first five years after admission (mean per patient cost: £46,039). There was fivefold
variation in the magnitude of costs between patients, ranging from £19,101 to £107,336. Costs increased with older age,
increasing stroke severity and intracerebral hemorrhage stroke. Increasing the proportion of eligible patients receiving
thrombolysis or early supported discharge was estimated to save health and social care costs by five years after stroke.
Discussion: The cost of stroke care is large and varies widely between patients. Increasing the proportion of eligible
patients receiving thrombolysis or early supported discharge could contribute to reducing the financial burden of stroke.
Conclusion: Extending stroke registers to report individualised data on costs may enhance their potential to support
quality improvement and research.
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Introduction
Stroke is one of the major global causes of mortality and
disability. Each year, 10 million people are estimated to
have a ﬁrst ever stroke, and 6.5 million people die as a
result of stroke.1 In the United Kingdom, stroke is the
third leading cause of years of life lost and of disability-
adjusted life years.2 This human burden is mirrored
by the very large cost of providing healthcare to
people with stroke, with stroke care accounting for
approximately 3–5% of all healthcare expenditure.3,4
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Many health systems are faced with the challenge of
tackling the rising costs of healthcare services, and it is
now increasingly recognised that cost is a fundamental
dimension of healthcare quality. Cost reduction is one
of the components of the Institute of Healthcare
Improvement’s ‘Triple Aim’5 and some have argued
that the concept of quality in healthcare should be
reframed in terms of ‘value’: health outcomes achieved
per unit of expenditure.6 Although registries have been
established in many settings7–9 to measure stroke care
and outcomes after stroke, they typically do not include
information about healthcare costs and are not specif-
ically designed to measure the value that healthcare
services provide.
The Sentinel Stroke National Audit Programme
(SSNAP) is the national stroke register of England,
Wales and Northern Ireland, collecting data on an esti-
mated 95% of all patients admitted to hospital with
acute stroke.10 It provides individualised data and ana-
lytics about the quality of stroke care to hospitals,
rehabilitation services, payers (‘Commissioners’ in the
terminology of the National Health Service), stroke
survivors and policy makers. The aims of this study
were to estimate patient-level health and social care
costs of stroke for all patients admitted to hospital
with stroke in England, Wales and Northern Ireland
and integrate this alongside near real-time reporting
of SSNAP data on quality of care and patient
outcomes.
Methods
The study was carried out in two phases (Figure 1).
Firstly, a health economic simulation was developed
to produce patient-level estimates of the health and
social care cost of acute stroke, taking account of
patient’s age, stroke type, stroke severity and sex.
Secondly, these estimates were integrated into
SSNAP, and interactive tools were developed to
model the health economic consequences of increasing
access to intravenous thrombolysis and early supported
discharge.
Figure 1. Design of the study.
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Health economic simulation
A detailed description of the health economic methods
is provided in the online Appendix and is summarised
below.
The model was a time-to-event individual patient
simulation model.11 In this model, patients go through
diﬀerent treatment units for healthcare (Table 1 and
Figure A1, online Appendix). Their health status,
stroke-related resource use and costs and outcomes
are modelled through the simulation, up to ﬁve years
after stroke.
The principal model parameters were: age, sex,
stroke type (ischaemic stroke and primary intracerebral
haemorrhage) and stroke severity. Health status as well
as other parameters including mortality, next event and
length of stay in each treatment unit were probabilis-
tically updated at the end of each treatment unit,
depending on their characteristics when entering the
unit. Health states were measured by the National
Institute of Health Stroke Score (NIHSS; a measure
of stroke severity) at stroke onset and then subse-
quently by the modiﬁed Rankin Score (mRS; a measure
of functional status). The change in mRS from before
to after the stroke was used to estimate change in dis-
ability caused by the stroke and attribute changes in
health and social care utilisation to the stroke itself
rather than pre-existing or co-morbid illnesses.
Health-Related Quality of Life (health utility on a
0–1 scale) was estimated by mapping from the mRS.12
Probabilities and distributions were largely esti-
mated using SSNAP data, with additional data on
long-term outcomes, stroke recurrence and resource
use obtained from the South London Stroke Register
(SLSR). SSNAP data included in the model included all
patients aged 40–100 years admitted for acute stroke
from April 2013 to 2015 (n¼ 111,846). The SLSR is a
population-based register with prospective long-term
follow-up of all adults with ﬁrst ever stroke in South
London,13 including data on 6000 patients. The SLSR
was used to provide data to model survival after stroke,
stroke recurrence and to estimate long-term health and
social care utilisation after stroke. Resource use was
estimated based on the parameters in Table 1, which
were combined with unit costs (online Appendix) to esti-
mate the costs generated by individuals in the model.
Cost estimates took a health and social care perspec-
tive (healthcare is free for users of the National Health
Service in the United Kingdom but social care may
incur charges). Unit costs for events and treatment
units were derived from existing cost sources (online
Appendix) and were not discounted due to the
relatively short time-horizon used. Quality-adjusted
life-years (QALYs), the primary health outcomes,
were estimated by weighting survival with health utility.
Health cost estimates included the costs of pre-hospital
care, acute care, diagnostics, prescribing, inpatient
rehabilitation, community rehabilitation, early sup-
ported discharge, primary care, secondary prevention
and stroke recurrence. Social care included nursing
home care, formal care at home, supported meals and
day services. The population mean of these costs and
QALY were then estimated according to 80 diﬀerent
combinations of baseline characteristics (age, sex,
stroke type and stroke severity).
Baseline results were estimated to reﬂect the current
situation of stroke care. Inputs estimated from SSNAP
were used directly for this purpose. Scenario analyses
were conducted to estimate the cost-eﬀectiveness results
of increasing the proportion of patients treated with
intravenous thrombolysis or early supported discharge
(online Appendix). The treatment eﬀects of thromboly-
sis and early supported discharge were then calibrated
to the results of Cochrane reviews of randomised con-
trolled trials of these interventions,14,15 by comparing
models using treatment eﬀects from the Cochrane
reviews to those obtained using the real-world treat-
ment eﬀects observed in SSNAP. Treatment eﬀects
reported by the Cochrane reviews were used to optimise
the inputs of the model. Mean healthcare cost, mean
social care cost and mean QALYs over all stroke
patients at one and ﬁve years after primary stroke
were plotted and the line of best ﬁt calculated to esti-
mate the cost savings and QALYs gained for each extra
person thrombolysed or discharged to ESD (online
Appendix). Probabilistic sensitivity analysis (PSA)
was conducted using Monte Carlo simulation to
assess uncertainty of our results and estimate 95% con-
ﬁdence intervals for the base case results.
Statistical analyses were carried out with R and
Stata 13, and the health economic model was built in
MS Excel VBA (2010).
Integration into SSNAP
All patients in SSNAP were assigned one of the model
subgroups based on sex, age group, stroke severity and
stroke type. The data were then linked with a table of
cost estimates from the health economics model to gen-
erate individualised cost estimates for all patients in
SSNAP. Total and average costs were integrated into
reports alongside SSNAP outputs describing quality of
care metrics and outcomes (survival, mRS at discharge,
new institutionalisation). SSNAP outputs incorporat-
ing health economic data include executive summaries
designed for hospital executive boards and dashboards
designed for commissioners. The results of the model
were illustrated for one year of SSNAP data (n¼ 84,184
patients admitted between April 2015 and March 2016),
plotting ﬁve-year health and social care cost against
age, stroke severity and stroke type.
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Ethics
Data analyses were carried out using fully anonymised
datasets from SSNAP and the SLSR. SSNAP has
approval from the Clinical Advisory Group of the
NHS Health Research Authority to collect patient-
level data under section 251 of the NHS Act 2006. All
patients or their relatives gave written informed consent
to participate in the SLSR. The design of the SLSR was
approved by the ethics committees of Guy’s and St
Thomas’ National Health Service Foundation Trust,
King’s College Hospital Foundation Trust, St
George’s University Hospital, National Hospital for
Nervous Diseases, and Westminster Hospital.
Results
The mean per-patient cost of healthcare attributable to
stroke was £13,452 in the ﬁrst year after stroke and
£17,963 after ﬁve years (Table 2). Mean social care
costs attributable to stroke were lower than healthcare
costs in the ﬁrst year (£8977) but by ﬁve years after
stroke social care costs accounted for the larger
burden of cost (£28,076). Total mean costs were
£22,429 by one year and £46,039 at ﬁve years.
In England, Wales and Northern Ireland, there were
84,184 patients admitted with stroke between April
2015 and March 2016 and entered onto SSNAP. Of
these, 73,318 (87.1%) had ischaemic stroke, 10,267
(12.2%) had ICH, 599 (0.7%) had undetermined
stroke type. Total health and social care costs attribut-
able to stroke for this cohort of patients were £1.74
billion at one year and £3.60 billion at ﬁve years.
The estimated stroke cost varied widely according to
patient characteristics, ranging from £7322 to £44,854
at one year and £19,101 to £107,336 at ﬁve years. Costs
increased with age and with stroke severity (Figure 2).
Mean costs were £4000 higher for ICH stroke than for
ischaemic stroke at one year and £11,000 higher by ﬁve
years (Figure 3)
Scenario analysis
We found that increasing the proportion of patients
receiving thrombolysis or early supported discharge
was cost saving, particularly for long-term social care
costs. For thrombolysis, we estimated healthcare sav-
ings of £3200 and £4000, social care savings of £2900
and £5300 and 0.08 and 0.26 QALYs gained in total for
each extra patient thrombolysed after one and ﬁve
years, respectively (Figure A2, online Appendix). For
ESD, the cost savings for health and social care were
estimated to be £1600 and £2400 after one year, £1600
and £8100 after ﬁve years, with QALY gains of 0.04
and 0.14 per at one and ﬁve years, respectively, for each
extra patient discharged with ESD (Figure A3, online
Appendix). In the sensitivity analyses, 95% conﬁdence
intervals were estimated for three scenarios: base case,
95% of the patients who met the SSNAP minimum
criteria were thrombolysed and 35% of patients who
were not discharged to ESD redirected to ESD treat-
ment (online Appendix).
We used these results to support quality improve-
ment and service development in stroke care services
by building interactive Excel tools for SSNAP partici-
pants (illustration of the thrombolysis tool in Figure 4).
These enable SSNAP participants to compare their own
data to the results of the health economic model and
estimate the potential cost eﬀectiveness of increasing
access to thrombolysis and ESD in their patient
cohorts. The tool allows participants to model diﬀerent
scenarios (such as increasing the number of patients
arriving at hospital within the thrombolysis time
window), allowing them to identify opportunities for
improvement.
Discussion
The care of patients with stroke is expensive, both at
the individual level and at the level of health systems
and society as a whole. These costs vary considerably
Table 2. Baseline mean costs per patient at one and five years.
1 Year 5 Year
Mean healthcare costs per patienta £13,452 £17,963
Mean social care costs per patientb £8977 £28,076
Mean total health and social care costs per patient £22,429 £46,039
Combined total cost for all patients included in SSNAP, April 2015–March 2016 (n¼ 84,184) £1,736,338,300 £3,604,672,200
Mean health and social costs per patient with ischaemic stroke £20,121 £41,432
Mean health and social costs per patient with ICH stroke £24,297 £52,726
ICH: intracerebral hemorrhage; SSNAP: Sentinel Stroke National Audit Programme.
aHealthcare costs include: ambulance, MRI or CT scan, thrombolysis, acute stroke unit care, rehabilitation stroke unit care, general medical ward care,
community rehabilitation, GP visits, secondary prevention, and ESD therapists.
bSocial care costs include: care home, home help, meals on wheels, and social service day centre visits.
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Figure 3. Five-year health and social cost age and stroke type, for all patients (n¼ 84,184) admitted between April 2015 and March
2016. Each dot on the scatter plot is one patient with stroke; the best fit line is a restricted cubic spline with four knots.
Figure 2. Five-year health and social costs by age and stroke severity, for all patients (n¼ 84,184) admitted between April 2015 and
March 2016. Each dot on the scatter plot is one patient with stroke; the best fit line is a restricted cubic spline with four knots.
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between patients, in the ﬁrst ﬁve years after stroke ran-
ging ﬁvefold between patient subgroups with the lowest
and highest care costs. Five-year costs were highest in
patients with haemorrhagic strokes, older patients and
those with more severe stroke. Costs were lowest in
patients with ischaemic stroke and mild strokes. Costs
over the ﬁrst year after stroke largely arise from the
costs of acute treatment, but over time the costs of
providing social care account for a greater proportion
of the total care costs of stroke. We found that both
thrombolysis and early supported discharge services
were both cost eﬀective and cost saving, resulting in
ﬁnancial savings to both the healthcare and social
care costs of stroke. Increasing the proportion of
patients receiving these interventions therefore has the
potential not only to improve patient outcomes after
stroke but also help to control the high ﬁnancial
burden of stroke.
As far as we are aware, this is the ﬁrst time that a
detailed patient-level health economic model has been
integrated into a large-scale stroke register. The devel-
opment of a stratiﬁed model enabled patient-level cost
estimates to take account of how costs vary according
to patients’ age, stroke type, stroke severity and sex,
rather than simply using an average across all patients.
By integrating this model into an existing stroke regis-
ter, we were able to extend SSNAP to report
patient-level data on estimated costs alongside data
about stroke care quality and outcomes. Although we
have not yet evaluated the eﬀectiveness and usefulness
of feeding back cost data in this way, the methodology
could be adopted by other stroke registries and has the
potential to expand the role of registries in supporting
quality improvement and research.
These cost estimates are consistent with previous
studies of the costs of stroke. Recent estimates of the
costs in high-income countries with health systems simi-
lar to the United Kingdom have reported costs in the
ﬁrst year after stroke of E29,484 in the Netherlands16
and E21,200 in Sweden.17 A previous national analysis
of stroke data in England in 2009 estimated a mean cost
of £28,568 (in 2017 prices).18 Since that time there have
been major changes in the organisation and delivery of
stroke care in the United Kingdom, resulting in reduced
length of stay, increase in the provision and use of
stroke units and greater use of interventions which
reduce long-term disability (e.g. thrombolysis)10 and
recurrence (e.g. antiplatelet therapy). These improve-
ments in care may have contributed to the reduction
in the estimated costs of stroke care since 2009.
Collecting data on large cohorts of patients, typically
at the regional or national level, registries are one of the
major sources of ‘real world data’ about human health
and healthcare services.19,20 It is too early to evaluate
Figure 4. Screenshot from the Thrombolysis tool.
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the impact of including data on health costs within a
large-scale clinical registry, but we anticipate that these
data will have several uses. For example, bespoke and
clearly sourced estimates of costs could be used by clin-
icians and managers to make business cases for quality
improvement or service development. Similarly, these
data make it simpler to estimate the ﬁnancial return
on investment in spending money on stroke prevention,
through for example detection and management of
atrial ﬁbrillation20 and in predicting the future ﬁnancial
burden of stroke care. These data could also be useful
in the planning, design and conduct of observational
and interventional research studies. For example,
embedding randomised controlled trials (RCTs)
within registries that include data on health economic
outcomes could help researchers carry out cheaper and
more useful RCTs of new interventions in stroke care21
and aid in the health economic evaluation of new
interventions.
Strengths and limitations
The strength of this study was that it estimated a fuller
range of costs than are usually available in healthcare
payment or reimbursement systems – in the UK, for
example, previous sources of stroke cost data included
only inpatient care but not the longer term costs of
rehabilitation, nursing and medical care. By making
use of the detailed real-world stroke data about
stroke collected through registries, we were able to
model stroke care with a level of detail that has typic-
ally not been possible in previous studies of the cost of
stroke.22
There are, however, a number of limitations. Firstly,
the model only takes a health and social care perspec-
tive and does not include the wider societal costs of
stroke (such as costs to patients or family members
through loss of income and informal care). Cost esti-
mates were also only based on patients who had a full
NIHSS score in SSNAP (76% out of the all stroke
patients). In comparison with the entire patient
population, these patients were slightly younger (med-
ian¼ 76 vs. 80) and slightly more independent (median
mRS¼ 0 vs. 1), likely resulting in a bias towards lower
cost estimates. Cost estimates were also based only on
patients aged above 40 years due to insuﬃcient data
being available in the SLSR of patients aged less than
40 years to ﬁt the models. In implementing these esti-
mates in SSNAP, we therefore assumed that costs in
younger patients are the same as for those aged 40–64
years. The model describes the typical care pathways
experienced by the majority of patients admitted with
acute stroke in the UK, but this is by necessity a sim-
pliﬁcation of the real world. For example, the model
assumes that all patients are admitted to a stroke unit,
and although this is true for 95% of stroke patients in
England, Wales and Northern Ireland,10 the model
does not take account of the 5% of patient which do
not. It also does not take account of the impact of
thrombectomy in patients with acute ischemic stroke.
Although in the UK this is still not in widespread use
and so is unlikely to have made a signiﬁcant diﬀerence
to current cost estimates, future estimates of the cost of
stroke should take account of this emerging therapy, as
it is likely to result in lower long-term costs.23 To gain
more power from the data, we combined all SSNAP
data collected from England, Wales, and Northern
Ireland and applied the same unit costs to all patients.
In the real world, costs might vary between these three
countries, although the diﬀerences are likely to be small
as their health systems are similar.
Conclusion
We developed and implemented a detailed health eco-
nomic model within a national stroke register. Not only
does this help to provide more up to date estimates of
the large ﬁnancial costs arising from stroke in the
United Kingdom, but provides new data about how
costs vary between patients and a new source of infor-
mation to help plan and improve stroke care services.
In particular, these results imply that improving access
to thrombolysis and early supported discharge services
can contribute to reducing the ﬁnancial burden of
stroke on health and social care services. Health eco-
nomic models are inevitably a simpliﬁcation of the real
world, and it is important to understand the assump-
tions that support the estimates from models such as
this. Nonetheless, integrating the measurement and
reporting of health economic outcomes data into clin-
ical registries could help them become increasingly
useful resources for quality improvement and research.
Data sharing
Data from SSNAP are available at www.strokeaudit.
org. This includes extensive and unrestricted access to
publicly available datasets and contact details to
request access to anonymised patient-level data.
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